China NMPA Inspection - Fuzhou Green Wildlife Technology Co., Ltd. - October 13, 2020

The National Medical Products Administration (NMPA), China's key regulatory authority for drugs and medical devices, issued an official notification on October 13, 2020, announcing an unannounced inspection targeting Fuzhou Lvyu Biotechnology Co., Ltd. This document, referenced under index number JGXX-2020-10001, primarily serves to make public the NMPA's regulatory activity concerning the aforementioned company. While the notification confirms the commencement or recent conclusion of an unannounced inspection, the provided content is restricted to the administrative details of this announcement. It explicitly identifies Fuzhou Lvyu Biotechnology Co., Ltd. as the subject of regulatory oversight. However, the notification does not furnish specific details regarding the exact dates when the inspection was conducted, nor does it outline any particular main violations, non-compliance issues, or adverse findings that may have been uncovered. Consequently, the document does not specify any required corrective actions or regulatory mandates imposed upon the company following the inspection. The regulatory framework under which this inspection falls is the comprehensive system governed by the NMPA, ensuring product safety and quality within China's pharmaceutical and cosmetic sectors. This notification underscores the NMPA's commitment to proactive, unannounced inspections as a critical tool for maintaining compliance and public health standards, even though the specific findings of this particular inspection are not detailed within this public announcement.